The Valley Desk

NCT04526106 · Interventional trial

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Overall registry status Completed

Phase 1 · Phase 2

Conditions Cholangiocarcinoma, FGFR2 Amplification, FGFR2 Gene Activation, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Mutation, FGFR2 Gene Translocation, Intrahepatic Cholangiocarcinoma, Other Solid Tumors, Adult

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov